Ranbaxy ready for re-inspection
This article was originally published in The Gold Sheet
Ranbaxy has asked FDA to re-inspect its Paonta Sahib and Dewas manufacturing sites in India, CEO Atul Sobti told PharmAsia News. The company has provided the agency a report explaining how it corrected problems FDA noted in previous inspections, and which led the agency in September to suspend imports of more than 30 products. A favorable re-inspection could enable Ranbaxy, now owned by Japanese drug maker Daiichi Sankyo, to resume U.S. exports (see "The Gold Sheet," March 2009, p. 11 and "The Gold Sheet," August 2008, p. 6)
You may also be interested in...
Time waits for no lab learn Ranbaxy and new owner Daiichi Sankyo as stock sinks after FDA sanctions firm for holding stability testing samples in refrigerators until its overworked lab could get around to testing them. Lab was backdating same-day testing of 30-, 60- and 90-day samples, FDA said as it slapped Ranbaxy with application integrity letter.
FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.